Show simple item record

dc.contributor.authorLærum, Dan
dc.contributor.authorBrustugun, Odd Terje
dc.contributor.authorGallefoss, Frode
dc.contributor.authorFalk, Ragnhild Sørum
dc.contributor.authorStrand, Trond-Eirik
dc.contributor.authorFjellbirkeland, Lars
dc.description.abstractBackground Small-cell lung cancer (SCLC) is an aggressive, rapidly progressive malignancy. Thus, expedient diagnosis and treatment initiation is important. This study identifies and quantifies factors associated with delayed diagnosis and treatment initiation in patients with SCLC and compares time to treatment in SCLC with a cohort of patients with non-small cell lung cancer (NSCLC). Materials and Methods The study included all patients diagnosed with SCLC at a hospital in southern Norway in a ten-year period (2007–2016), and all NSCLC patients during the period 2013–2016. Total time to treatment (TTT), was defined as the number of days from date of referral due to suspicion of lung cancer to first day of treatment. Factors associated with prolonged TTT were estimated using multivariate median regression analysis. Results The median TTT and interquartile range (IQR) for the 183 patients with SCLC was 16 (10–23) days. Factors associated with delayed TTT included outpatient versus inpatient evaluation (+8.4 days), number of diagnostic procedures (+4.3 days per procedure), stage I-III versus stage IV (+3.6 days) and age (+2.1 days per 10 years). In 2013–16, TTT in SCLC was 3.5 days shorter than in the period before and less than half that of NSCLC in the same period, 15 (9–22) versus 33 (22–50) days (p = 0.001). Conclusion Shorter TTT is seen in higher stage, while longer TTT is a result of increasing complexity of the diagnostic process and treatment decisions of patients with curative intent treatment. Knowledge on delaying factors can shorten TTT and improve clinical practice.en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.titleFactors associated with delayed treatment initiation in an unselected cohort of patients with small-cell lung canceren_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.source.journalCancer Treatment and Research Communicationsen_US
dc.identifier.citationCancer Treatment and Research Communications. 2021, 29, 100477.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal